Muhammad Qaseem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhammad Qaseem has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Haseeb Hasan
Department of Medicine King Edward Medical University Lahore Pakistan
4 shared publications - Shehbaz Ali
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
3 shared publications - Naveed Ahmad
Khyber Medical College, Peshawar, Pakistan
2 shared publications - Abdul Qayum Khan
Department of medicine, Saidu Medical College, Swat, Pakistan
1 shared publication - Abdullah Afridi
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
1 shared publication - Aleena Amir Malik
Department of Medicine, United Medical and Dental College, Karachi, Sindh, Pakistan
1 shared publication
Latest Publications
- Open Access
- 9 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (41) , e50994
Metallic versus plastic stents for the management of biliary obstruction
Background: Biliary obstruction can be managed with metallic stents (MS) or plastic stents (PS), but comparative evidence across benign and malignant conditions remains uncertain. We conducted a systematic review and meta-analysis comparing MS and PS. Methods: PubMed, Embase, Scopus, Web of Science, and Cochrane CENTRAL were searched from inception to the search date. Randomized controlled trials and observational studies comparing MS with PS in patients with benign or malignant biliary obstruction were eligible. Primary analyses compared MS with PS across the overall eligible population, including both benign and malignant obstruction. Where sufficient outcome-specific data were available, subgroup analyses were performed according to disease etiology (benign vs malignant). Outcomes included functional success, adverse events, recurrent biliary obstruction (RBO), procedure time, and overall survival. Meta-analysis was performed with Hartung–Knapp sensitivity analyses. Results: Nine studies comprising 890 participants were included. Functional success was comparable between MS and PS (RR = 1.03, 95% confidence intervals [CI]: 0.96–1.11). Among 8 studies contributing adverse-event data, no significant difference was observed (RR = 1.37, 95% CI: 0.92–2.03; P = .123; I 2 = 45.4%). Adverse events were higher with MS in malignant disease (RR = 1.74, 95% CI: 1.15–2.63) but not benign disease (RR = 1.01, 95% CI: 0.83–1.23; P for subgroup difference = .020). Hartung–Knapp analysis remained non-significant (RR = 1.37, 95% CI: 0.96–1.95; P = .078). MS showed a lower risk of RBO (RR = 0.61, 95% CI: 0.32–1.17; I 2 = 93.1%), supported by Hartung–Knapp analysis (RR = 0.61, 95% CI: 0.41–0.91). Conclusion: MS and PS demonstrated comparable functional success and overall adverse-event rates, although adverse events were higher with MS in malignant disease. MS may improve stent durability, but substantial heterogeneity limits certainty. Available studies did not demonstrate a consistent survival advantage. Further randomized trials are warranted.
- 9 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (41) , e50994
Open AccessMetallic versus plastic stents for the management of biliary obstruction
Background: Biliary obstruction can be managed with metallic stents (MS) or plastic stents (PS), but comparative evidence across benign and malignant conditions remains uncertain. We conducted a systematic review and meta-analysis comparing MS and PS. Methods: PubMed, Embase, Scopus, Web of Science, and Cochrane CENTRAL were searched from inception to the search date. Randomized controlled trials and observational studies comparing MS with PS in patients with benign or malignant biliary obstruction were eligible. Primary analyses compared MS with PS across the overall eligible population, including both benign and malignant obstruction. Where sufficient outcome-specific data were available, subgroup analyses were performed according to disease etiology (benign vs malignant). Outcomes included functional success, adverse events, recurrent biliary obstruction (RBO), procedure time, and overall survival. Meta-analysis was performed with Hartung–Knapp sensitivity analyses. Results: Nine studies comprising 890 participants were included. Functional success was comparable between MS and PS (RR = 1.03, 95% confidence intervals [CI]: 0.96–1.11). Among 8 studies contributing adverse-event data, no significant difference was observed (RR = 1.37, 95% CI: 0.92–2.03; P = .123; I 2 = 45.4%). Adverse events were higher with MS in malignant disease (RR = 1.74, 95% CI: 1.15–2.63) but not benign disease (RR = 1.01, 95% CI: 0.83–1.23; P for subgroup difference = .020). Hartung–Knapp analysis remained non-significant (RR = 1.37, 95% CI: 0.96–1.95; P = .078). MS showed a lower risk of RBO (RR = 0.61, 95% CI: 0.32–1.17; I 2 = 93.1%), supported by Hartung–Knapp analysis (RR = 0.61, 95% CI: 0.41–0.91). Conclusion: MS and PS demonstrated comparable functional success and overall adverse-event rates, although adverse events were higher with MS in malignant disease. MS may improve stent durability, but substantial heterogeneity limits certainty. Available studies did not demonstrate a consistent survival advantage. Further randomized trials are warranted.
- Open Access
- 7 June 2026
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 28 (6) , e70304
Biological and Heart Age Acceleration in CKM Syndrome: Promising Stroke Predictors or Methodological Concerns?
- 7 June 2026
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 28 (6) , e70304
Open AccessBiological and Heart Age Acceleration in CKM Syndrome: Promising Stroke Predictors or Methodological Concerns?
- Open Access
- 3 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4754-4755
Antiphospholipid syndrome-associated myocarditis: role of 18F-FDG PET/CT in differentiation from immune-mediated or viral etiologies
Was not provided for this article.
- 3 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4754-4755
Open AccessAntiphospholipid syndrome-associated myocarditis: role of 18F-FDG PET/CT in differentiation from immune-mediated or viral etiologies
Was not provided for this article.
- Open Access
- 3 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4767-4768
Daraxonrasib in metastatic pancreatic cancer (RASolute 302): survival breakthrough or real-world access barrier?
Was not provided for this article.
- 3 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4767-4768
Open AccessDaraxonrasib in metastatic pancreatic cancer (RASolute 302): survival breakthrough or real-world access barrier?
Was not provided for this article.
- Open Access
- 21 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4759-4760
From pancreatic ductal adenocarcinoma to non-small cell lung cancer: daraxonrasib in the RASolute 302 trial – a pan-RAS(ON) breakthrough or the next evolution in targeting diverse oncogenic RAS variants?
Was not provided for this article.
- 21 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4759-4760
Open AccessFrom pancreatic ductal adenocarcinoma to non-small cell lung cancer: daraxonrasib in the RASolute 302 trial – a pan-RAS(ON) breakthrough or the next evolution in targeting diverse oncogenic RAS variants?
Was not provided for this article.
- Open Access
- 16 May 2026
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 28 (5) , e70294
Neprilysin and Hypertension: Cause, Consequence, or Marker?
- 16 May 2026
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 28 (5) , e70294
Open AccessNeprilysin and Hypertension: Cause, Consequence, or Marker?
- Open Access
- 11 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3913-3914
Semaglutide-induced lean mass loss: clinical concern or physiological adaptation
- 11 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3913-3914
Open AccessSemaglutide-induced lean mass loss: clinical concern or physiological adaptation
- Open Access
- 17 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3825-3826
Targeting the BlyS/APRIL axis in neuro-Behçet disease: a rationale for telitacicept as a steroid-sparing strategy
- 17 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3825-3826
Open AccessTargeting the BlyS/APRIL axis in neuro-Behçet disease: a rationale for telitacicept as a steroid-sparing strategy